Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT

JAK1/2 inhibitor ruxolitinib (RUX) is approved in patients with myelofibrosis but the impact of pretreatment with RUX on outcome after allogeneic hematopoietic stem cell transplantation (HSCT) remains to be determined. We evaluated the impact of RUX on outcome in 551 myelofibrosis patients who recei...

Descripción completa

Detalles Bibliográficos
Autores principales: Kröger, Nicolaus, Sbianchi, Giulia, Sirait, Tiarlan, Wolschke, Christine, Beelen, Dietrich, Passweg, Jakob, Robin, Marie, Vrhovac, Radovan, Helbig, Grzegorz, Sockel, Katja, Conneally, Eibhlin, Rubio, Marie Thérèse, Beguin, Yves, Finke, Jürgen, Bernasconi, Paolo, Morozova, Elena, Clausen, Johannes, von dem Borne, Peter, Schaap, Nicolaas, Schroyens, Wilfried, Patriarca, Francesca, Di Renzo, Nicola, Yeğin, Zeynep Arzu, Hayden, Patrick, McLornan, Donal, Yakoub-Agha, Ibrahim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8632691/
https://www.ncbi.nlm.nih.gov/pubmed/34023851
http://dx.doi.org/10.1038/s41375-021-01276-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8632691/
https://www.ncbi.nlm.nih.gov/pubmed/34023851
http://dx.doi.org/10.1038/s41375-021-01276-4

Ejemplares similares